Research Committee on Disorders of Adrenal Hormones, Research on Intractable Diseases, Health and Labour Sciences Research Grants, Tokyo, Japan.
Disorders of Sex Development and Adrenal Disorders Committee, the Japanese Society for Pediatric Endocrinology, Fushimi-ku, Kyoto, Japan.
J Clin Endocrinol Metab. 2020 Nov 1;105(11). doi: 10.1210/clinem/dgaa557.
Lipoid congenital adrenal hyperplasia (LCAH) is caused by mutations in STAR. Classic (CLCAH) and nonclassic (NCLCAH) forms were reported as total and partial deficiencies, respectively, of adrenal and gonadal steroid hormones. The rarity of LCAH has precluded large-scale epidemiological and clinical investigations.
To determine the epidemiological and clinical characteristics of 2 forms of LCAH.
A multicenter cross-sectional cohort study in Japan on December 1, 2017.
Fifty-seven patients with LCAH (median age, 23.7 years; range, 0.0-47.5 years).
Patient demographics, STAR genotype, Quigley grade, endocrinological and imaging data, treatment, and prognosis.
Fifty-three and 4 patients fulfilled definite and probable diagnostic criteria for LCAH, respectively. When NCLCAH was defined as either Quigley grade 1 in XY karyotype, no episode of salt losing or requirement of fludrocortisone, or onset of primary adrenal insufficiency (PAI) at 1 year or older, patients were divided into groups of 43 patients with CLCAH (75.4%), 11 with NCLCAH (19.3%), and 3 with unclassified LCAH (5.3%). All of the patients with CLCAH and 7/11 NCLCAH (63.6%) were treated with fludrocortisone. CLCAH was diagnosed at a significantly younger age than NCLCAH (median, 0.0 vs 4.0 years). STAR-Arg272Cys or -Met225Thr was identified only in NCLCAH (8/11, 72.7%).
We demonstrated the relative proportions and clinical and molecular characteristics of NCLCAH and CLCAH in Japan. These criteria for NCLCAH correspond to all previously published cases and our cases whose masculinization of the external genitalia, ability of mineralocorticoid production, and onset of PAI were described.
脂质型先天性肾上腺皮质增生症(LCAH)是由 STAR 基因突变引起的。经典型(CLCAH)和非经典型(NCLCAH)分别被报道为肾上腺和性腺类固醇激素的完全和部分缺乏。LCAH 的罕见性使得大规模的流行病学和临床研究变得不可能。
确定 2 种 LCAH 形式的流行病学和临床特征。
2017 年 12 月 1 日在日本进行的多中心横断面队列研究。
57 例 LCAH 患者(中位年龄 23.7 岁;范围 0.0-47.5 岁)。
患者人口统计学资料、STAR 基因型、Quigley 分级、内分泌和影像学数据、治疗和预后。
53 例和 4 例患者分别符合 LCAH 的明确和可能诊断标准。当 NCLCAH 被定义为 XY 核型中的 Quigley 分级 1、无盐丢失发作或需要氟氢可的松、或原发性肾上腺功能不全(PAI)在 1 岁或以上发病时,患者被分为 43 例 CLCAH 组(75.4%)、11 例 NCLCAH 组(19.3%)和 3 例未分类 LCAH 组(5.3%)。所有 CLCAH 患者和 11 例 NCLCAH 中的 7 例(63.6%)接受了氟氢可的松治疗。CLCAH 的诊断年龄明显小于 NCLCAH(中位数,0.0 岁 vs 4.0 岁)。仅在 NCLCAH 中发现 STAR-Arg272Cys 或 -Met225Thr 突变(8/11,72.7%)。
我们展示了日本 NCLCAH 和 CLCAH 的相对比例以及临床和分子特征。这些 NCLCAH 的标准与所有先前发表的病例以及我们描述过的外生殖器男性化、盐皮质激素产生能力和 PAI 发病的病例相对应。